According to Onconova Therapeutics's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 3.48. At the end of 2024 the company had a P/S ratio of 93.9.
Year | P/S ratio | Change |
---|---|---|
2024 | 93.9 | 35.46% |
2023 | 69.3 | 15.9% |
2022 | 59.8 | -74.64% |
2021 | 236 | -36.8% |
2020 | 373 | 1812.12% |
2019 | 19.5 | 100.05% |
2018 | 9.75 | -52.51% |
2017 | 20.5 | 641.98% |
2016 | 2.77 | 30.1% |
2015 | 2.13 | -97.62% |
2014 | 89.3 | 72.14% |
2013 | 51.9 |